TY  - JOUR
AU  - Galldiks, Norbert
AU  - Langen, Karl-Josef
AU  - Albert, Nathalie L
AU  - Chamberlain, Marc
AU  - Soffietti, Riccardo
AU  - Kim, Michelle M
AU  - Law, Ian
AU  - Le Rhun, Emilie
AU  - Chang, Susan
AU  - Schwarting, Julian
AU  - Combs, Stephanie E
AU  - Preusser, Matthias
AU  - Forsyth, Peter
AU  - Pope, Whitney
AU  - Weller, Michael
AU  - Tonn, Jörg C
TI  - PET Imaging in Patients with Brain Metastasis - Report of the RANO/PET Group
JO  - Neuro-Oncology
VL  - 21
IS  - 5
SN  - 1523-5866
CY  - Oxford
PB  - Oxford Univ. Press
M1  - FZJ-2019-00086
SP  - 585-595
PY  - 2019
AB  - Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.
LB  - PUB:(DE-HGF)16
C6  - pmid:30615138
UR  - <Go to ISI:>//WOS:000473768600005
DO  - DOI:10.1093/neuonc/noz003
UR  - https://juser.fz-juelich.de/record/859196
ER  -